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A B S T R A C T
Mucopolysaccharidosis II (MPS II) is a lysosomal storage disorder (LSD), caused by iduronate 2-sulphatase (IDS)
enzyme dysfunction. The neuropathology of the disease is not well understood, although the neural symptoms
are currently incurable. MPS II-patient derived iPSC lines were established and differentiated to neuronal
lineage. The disease phenotype was confirmed by IDS enzyme and glycosaminoglycan assay. MPS II neuronal
precursor cells (NPCs) showed significantly decreased self-renewal capacity, while their cortical neuronal dif-
ferentiation potential was not affected. Major structural alterations in the ER and Golgi complex, accumulation
of storage vacuoles, and increased apoptosis were observed both at protein expression and ultrastructural level
in the MPS II neuronal cells, which was more pronounced in GFAP + astrocytes, with increased LAMP2 ex-
pression but unchanged in their RAB7 compartment. Based on these finding we hypothesize that lysosomal
membrane protein (LMP) carrier vesicles have an initiating role in the formation of storage vacuoles leading to
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impaired lysosomal function. In conclusion, a novel human MPS II disease model was established for the first
time which recapitulates the in vitro neuropathology of the disorder, providing novel information on the disease
mechanism which allows better understanding of further lysosomal storage disorders and facilitates drug testing
and gene therapy approaches.
1. Introduction
One of 40 currently known lysosomal storage diseases (LSDs),
Mucopolysaccharidosis type II (MPS II; also known as Hunter syn-
drome; OMIM 309900) is registered on ORPHANET as a rare disease
[1]; its incidence rate is 1–100,000 worldwide [2] and 1 to 166,000 in
Europe [3]. MPS II is an X-linked, recessive disorder that manifests
almost exclusively in males, while female carriers with a mutant and a
wild-type allele are usually unaffected [4,5]. The disease is caused by
deficient activity of iduronate 2-sulphatase (IDS), a lysosomal enzyme
involved in the first step of the degradation pathway of the heparan and
dermatan sulphate proteoglycans [6]. Deficient IDS activity results in
the accumulation of glycosaminoglycans (GAGs), ultimately leading to
a cascade of multisystemic disease manifestations, especially in the
membrane of the cells, due to their central role in the creation of the
extracellular matrix (ECM) [7]. GAG fragments generated by alter-
native pathways are excreted in urine and other body fluids [8].
MPS II is a progressive disease characterized by musculoskeletal ab-
normalities (skeletal malformations, cardiac disease, stiffness and joint
contractures), organomegaly (enlarged spleen and liver), pulmonary dis-
orders, hearing loss, eye troubles and profound neurological dysfunction in
∼75% of patients [9]. Patients appear healthy at birth, with detectable
initial symptoms manifesting between 18 months and 4 years of age,
leading to a premature death. In relation to the pathogenicity of the IDS
mutation, a wide spectrum of the disorder has been described with dif-
ferent onset and severity [6,10,11]. The disease is diagnosed by quantifi-
cation of GAG excretion in urine or blood, or in cerebrospinal fluid (CSF),
but there is currently no cure and the available treatments are mostly
palliative, although there are two primary treatment options. The first,
allogenic hematopoietic stem cell transplantation (HSCT) can alleviate the
symptoms of MPS II [12,13], reducing urinary GAG levels, stabilizing
heart function (cardiac valvular regurgitation may decrease), and im-
proving hearing, but its efficacy on cognitive function is still debated.
However, a new gene-therapy approach, using ex-vivo genome editing by
CRISP/Cas9 technology, introduced the lysosomal enzyme iduronidase
(IDUA) to the CCR5 safe harbor locus in human CD34+hematopoietic
stem cells. The IDUA overexpressing cells were transplanted into an im-
munocompromised mouse model of MPS I, resulting in endogenous en-
zyme expression, correct the biochemical, visceral, musculoskeletal, and
neurologic manifestations of the disease [14]. Engineering the patient's
own hematopoietic cells to express the deficient enzyme properly and in
that way correcting the enzyme defect and stopping the progression of the
disease has great potential and could provide a new therapeutic approach
for further LSDs as well [15]. The second, enzyme replacement therapy
(ERT), involves the weekly intravenous administration of recombinant
human IDS enzyme (Elaprase™; Shire Human Genetic Therapies, Inc.), and
may improve growth, joint movement, respiratory function, vision, and
reduce pain sense and liver/spleen enlargement [16]. A major limitation
of ERT, however, is that the enzyme is not able to penetrate the blood-
brain barrier (BBB), and so cannot protect against lesions of the central
nervous system (CNS) or consequently against psychomotor regression
that leads to severe neurodegenerative abnormalities [17,18]. Clinical
trials on the delivery of the enzyme into the CSF via intrathecal admin-
istration and gene therapy approaches are ongoing. The development of
alternative, more effective treatment options for MPS II requires a better
understanding of its pathophysiology at the neuronal level.
An MPS II-comparable mouse model of MPS VII showed that GAG
accumulation caused by β-glucuronidase deficiency did not alter the
neuronal differentiation potential [19], while neural stem cells (NSCs)
derived from an IDS knock-out, MPS II mouse model displayed a self-
renewal capacity with a remarkably higher dependence on the culture
medium mitogens, suggesting that IDS deficit could hamper normal
differentiation. Indeed, during differentiation, IDS-deficient NSCs dis-
played an increasing and robust accumulation of lysosomal organelles
that was absent in control cells [20]. Interestingly, in healthy cells both
IDS expression and activity peaked at the progenitor stage leading to
the speculation that IDS could prime the correct commitment of tran-
sient progenitors and/or contribute to the establishment of an extra-
cellular environment suitable for functional differentiation and survival
of mature neurons. Moreover, when different cell types were analysed,
a glial cell-mediated neurodegeneration was shown to be involved as a
possible pathomechanism of MPS II [21,22]. Although these results in
an MPS II mouse model are important, species-specific differences ap-
pearing mainly in the CNS would require a faithful human model which
is not yet available.
In this study we raised the question whether the neuronal patho-
mechanism of MPS II disease can be modelled in an in vitro system
through patient-derived iPSC lines. Our goal was to establish an MPS II
specific iPSC-based in vitro model and to examine whether it re-
capitulates the disease phenotype. Ultrastructural morphology of MPS
II peripheral blood mononuclear cells (PBMCs), iPSC derived NPCs and
terminally differentiated (TD) cortical neuronal cells were evaluated.
The relationship between storage vacuoles and endosomal-lysosomal
system was also investigated. Our results may explain the origin of
storage vacuoles and the cellular pathomechanism of neurodegenera-
tion, as well as suggest further research/development directions.
2. Methods
2.1. Chemicals
The chemicals were purchased from Sigma-Aldrich (St Louis, MO,
USA) and all cell culture reagents from Thermo Fisher Scientific Inc.
(Waltham, MA, USA), unless otherwise specified.
2.2. Cell lines
In each assay, a healthy donor-derived iPSC line (originated from a 32-
years old Caucasian female) was used as control (Ctrl), which was gen-
erated by the same process as the disease-specific iPSCs (Fig. S1). The
disease-specific iPSC lines of this study were established and published
earlier by us: MPSII-1.3 [23], MPSII-2.5 [24], MPSII-4.1 [25], and Ctrl-M.1
[26]. Briefly, the MPSII-1.3 and MPSII-2.5 lines were generated from male
donor siblings (1- and 3 years-old, respectively) carrying the same muta-
tion (NM_000202.7(IDS):c.85C > T, p.Gln29Ter) [23,24], while Ctrl-M.1
(MPSII-mother.1) was derived from the PBMCs of their mother (39-years
old), who is an unaffected carrier [26]. The MPSII-4.1 line was derived
from an unrelated male patient (7-years old) with the disease, carrying a
different point mutation (NM_000202.7(IDS):c.182C > T, p.Ser61Phe) as
published earlier [25].
2.3. Human iPSC culture
Cells were cultured at 37 °C in a humidified atmosphere containing
5% CO2. The iPSCs were cultured on Matrigel (BD Biosciences, Franklin
Lakes, NJ, USA) with mTeSR-1 medium (Stem Cell Technologies,
Vancouver, Canada), using the clump-passage system, according to the
manufacturer's instructions.
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2.4. Neuronal differentiation and maintenance
The iPSCs were differentiated to neuronal progenitor cells (NPCs) by
the dual SMAD inhibition procedure [27], following the detailed pro-
tocol of Shi et al. [28]. In brief, until day 10 of differentiation, 10 μM
SB431542, 500 ng/mL Noggin (R&D Systems, Inc., Minneapolis, MN,
USA) and 5 ng/mL bFGF in neural induction medium (NIM; DMEM/
F12: Neurobasal medium, supplemented with 1xN2 and 2xB27, 2Mm
glutamine, 1× non-essential amino acid (NEAA), 100 μM β-mercap-
toethanol, 5 μg/mL insulin) was used to induce the neuroectodermal
lineage. Tissue culture plates were coated with poly-L-ornithine and
laminin (POL/L; 0.002%/1 μg/cm2). The forming neuronal rosette-like
structures were manually picked under a sterile microscope (Olympus
SZX2; Olympus Corporation, Shinjuku, Japan) and re-plated onto POL/
L plates. NPCs were expanded in neural maintenance medium (NMM;
DMEM-F12: Neurobasal medium, supplemented with 1xN2 and 2xB27,
2Mm glutamine, 1xNEAA), supplemented with 10 ng/mL bFGF and
10 ng/mL EGF. NPCs were passaged when reached 100% confluence,
using Accutase and single cell-seeded (50,000 cells/cm2) for further
expansion.
NPCs were terminally differentiated (TD) towards cortical neurons
by harvesting the cells using Accutase and plating them on POL/L
(0.002%/2 μg/cm2) at a seeding density of 40,000 cells/cm2 with NMM
medium [28]. The medium was changed every 3–4 days for up to 5
weeks (35 days, labelled as TD35). To note, both NIM and NMM media
was serum-free, no FBS was used in the cell cultures.
2.5. Immunocytochemistry (ICC) staining
The expression of neural markers was analysed using conventional
ICC staining. The cells were fixed in 4% PFA (20min, RT), permeabi-
lized with 0.1% Triton X-100 (5min) and blocked in 1% bovine serum
albumin (BSA) containing PBS (1 h, RT). The cells were incubated with
primary antibodies (O/N, 4 °C) and visualized with secondary anti-
bodies (listed in Table S3). For nuclei counterstaining 0.2 μg/mL DAPI
(20min, RT) was used. The cells were observed under a fluorescence
microscope equipped with a 3D imaging module, (AxioImager system
with ApoTome, Carl Zeiss MicroImaging GmbH, Jena, Germany) con-
trolled by AxioVision 4.8.1 Microscope software (Carl Zeiss).
2.6. Fluorescence activated cell sorting (FACS)
NPCs were collected using 0.5% trypsin to get a single cell sus-
pension and were fixed in 4% paraformaldehyde (PFA; 20min, RT).
After fixation, the cells were permeabilized with 0.2% Triton X-100
(5min, RT); followed by blocking with 1% BSA (15min, RT). The cells
were then incubated with the corresponding antibodies for 1 h at RT.
For unconjugated primary antibodies the isotype specific secondary
antibodies were used accordingly (see Table S3). To measure cell pro-
liferation, cells were treated with ice cold 70% ethanol (20min) and
stained (20min, RT) with FITC anti-human Ki67 antibody (Miltenyi
Biotec, Bergisch Gladbach, Germany). Samples were analysed using a
‘Cytomics FC 500’ Flow Cytometer (Beckman Coulter). Data were
analysed using FlowJo software (version 7.6.5; FlowJo, LLC).
2.7. Caspase 3/7 assay
To detect the activated Caspase-3/7 in neuronal cultures, live TD35
neurons were incubated with the CellEvent™ Caspase-3/7 Green
Detection Reagent for 30min (5 μM at 37 °C) according to the manu-
facturer's protocol and grown in POL/L (0.002%/2 μg/cm2) treated 96-
well plates (40,000 cells/cm2 density). For a positive control, cell cul-
tures were treated with 0.5 μM Staurosporine in the presence or absence
of the Caspase 3/7 Inhibitor 1 (10 μM for 2 h; MERCK, Kenilworth, NJ.
USA). Cell cultures were analysed using a Varioskan Flash (Thermo
Fisher Scientific) microplate reader (Ex/Em: 502/530 nm).
2.8. Fluorometric IDS enzyme assay
PBMCs, iPSCs and NPCs were used in the determination of IDS en-
zyme activity. The homogenates were prepared by sonication, and the
protein concentration was determined by the Pierce™ BCA Protein
Assay Kit and measured by spectrophotometer. Iduronate-2-sulphate
enzyme activity was assayed using fluorogenic substrate 4-methy-
lumbelliferyl-α-L-iduronate-2-sulphate, according to the method de-
scribed by Voznyi et al. [29].
2.9. GAG assay
Sulphated proteoglycans and glycosaminoglycans (sGAG) were
quantified by using the Blyscan™ Glycosaminoglycan Assay (Biocolor
Ltd., Carrickfergus, UK) following the manufacturer's instructions. NPCs
or terminally differentiated neuronal cultures were grown on 6-well
plates in 4 parallels for each experiment. Samples were measured with a
Varioskan Flash (Thermo Fisher Scientific) microplate reader and the
results were analysed using its software (SkanIt Software).
2.10. Western blot
The cell cultures were lysed with RIPA Lysis and Extraction Buffer
supplemented with Halt™ Protease and Phosphatase Inhibitor Cocktail
and Pierce™ Universal Nuclease for Cell Lysis (all from Thermo Fisher
Scientific), sonicated and the total protein concentration determined
using a Pierce BCA Protein Assay Kit. Protein samples (2–5 μg/sample)
were separated on 12% SDS-polyacrylamide gels and transferred to
Immun-Blot® PVDF Membrane (Bio-Rad, Hercules, CA, USA). The
membranes were blocked with TBST (20mM Tris-HCl pH 7.4, 150mM
NaCl, 0.1% Tween-20) containing 5% low-fat dried milk (1 h, RT), then
incubated overnight at 4 °C with primary antibodies (Table S4). After
washing with TBST, the membranes were incubated with horseradish
peroxidase (HRP)-conjugated secondary antibodies 1:2000 (Sigma Al-
drich) for 1 h (RT). Signals were detected with SuperSignal™ West Dura
Extended Duration Substrate (Thermo Fisher Scientific) by KODAK Gel
Logic 1500 Imaging System and Kodak MI SE imaging software. Den-
sitometry measurement of protein bands intensity was carried out using
Image Studio™ Lite software (LI-COR; LI-COR Biosciences, Lincoln,
Nebraska, USA).
2.11. Nanogold particle uptake
NPCs were cultured in the presence of 0.5 µ M TMA (11-
Mercaptoundecyl)-N,N,N-trimethylammonium bromide) 5 nm nano-
gold particles [30,31] in NMMmedia supplemented with EGF and bFGF
for 12 and 24 h, then fixed and handled as detailed in electron micro-
scopy section [32–34].
2.12. Electron microscopy
Frozen PBMCs were thawed, centrifuged in chilled PBS buffer, then
30% BSA was applied to ‘glue’ the cells and the pellets were fixed with
5% glutaraldehyde in 0.1M cacodylate buffer (pH 7.4; 1 h, RT). NPCs
were detached from the surface by Dispase treatment and pelleted by
centrifugation, while terminally differentiated cortical neurons grown
on coverslips in 24-well tissue culture plates were fixed with solution
containing 3.2% PFA, 0.2% glutaraldehyde, 1% sucrose, 40mM CaCl2
in 0.1M cacodylate buffer. Samples for ultrastructural analysis were
post-fixed with 1% ferrocyanide-reduced osmium tetroxide [35], de-
hydrated using a graded ethanol series, then embedded in Spurr low
viscosity epoxy resin medium. Ultrathin sections were collected on
Formvar (Agar Sci., Essex, UK) coated copper slot grids, counterstained
with uranyl acetate and Reynolds's lead citrate, and examined on a
JEOL JEM 1011 transmission electron microscope equipped with a
Morada 11-megapixel camera (Olympus) using iTEM software.
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Fig. 1. Comparison of healthy and MPS II iPSC derived NPC and TD35 neuronal cultures. a) Neuronal precursor cells (NPCs) were differentiated from iPSC lines
stained with PAX6 (green) NESTIN (red) and SOX1 (magenta) antibodies. Nuclei were counterstained with DAPI (in blue). Scale bar: 20 μm; b) RT-qPCR analysis of
PAX6 and NESTIN transcripts showed similar expression in early passage NPCs. Values are expressed as relative expression normalized to the Ctrl, set as 1. Data are
presented as mean ± SEM (n = 3). *p < 0.05; c) TD35 neuronal cultures were characterized by immunocytochemical staining TUBB3 (green)/MAP2 (red), NF200
(green)/MAP2 (red), PSD95 (green)/MAP2 (red) and GFAP (green)/AQP4 (red). Nuclei were counterstained with DAPI (in blue). Scale bar: 20 μm; d) Representative
ultrastructural morphology picture of an active synapse in Ctrl TD35 neurons. Symmetric synapse with accumulating synaptic vesicles (SyV) in presynaptic terminal
and electron-dense material in synaptic cleft (SyC). Active zone is indicated by docking synaptic vesicles (white arrowheads) Scale bar: 100 nm; e) Expression of
neuronal marker genes in patient and control iPSCs-derived TD35 neuronal cultures evaluated by RT-qPCR. Values are expressed as relative expression normalized to
the Ctrl, set as 1. Note the different values of the y-axis. Data are presented as mean ± SEM (n = 3). *p < 0.05.
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For samples destined for immunogold labelling, an LRG embedding
procedure with a progressive temperature decrease (to preserve mem-
branes and antigenicity of proteins) was used (modification of the
method described by Berryman and Rodewall) [36].
2.13. Post-embedding immunolabeling of ultrathin sections
Ultrathin sections (60–80 nm) were collected on Formvar coated
200 mesh nickel grids. Antigen retrieval was achieved by exposure to
5% hydrogen peroxide (5min) and incubation in 1% sodium borohy-
dride and 50mM glycine dissolved in TBS (10min) before blocking (3%
milk powder and 1% BSA in TBS, 30min). The sections were incubated
overnight with primary antibodies diluted in TBS supplemented with
1.5% milk powder and 0.5% BSA (Table S5). All primary antisera were
polyclonal and developed in the rabbit against human peptides or
peptide sequences. The sections were then incubated for 6 h with anti-
rabbit 10 nm gold-conjugated IgG secondary antibody (1:100; dissolved
in TBS supplemented with 1% BSA) before being counterstained and
examined as described above.
2.14. RT-qPCR analysis
Total RNA was isolated from NPC and neuronal cultures (TD35)
using the RNeasy Plus Mini Kit (Qiagen, Hilden, Germany). For the
reverse transcription, 600 ng isolated RNA was used with the Maxima
First Strand cDNA Synthesis Kit for RT-qPCR with dsDNase (Thermo
Fisher Scientific) according to the manufacturer's instructions.
Primers were optimized using two-fold serial dilution standard
curves. GAPDH was used as the reference gene (Table S6). Each real-
time PCR reaction contained 5 ng RNA equivalent cDNA template,
400 nM of each primer and 50% SYBR Green JumpStart Taq ReadyMix
(Sigma Aldrich) in a total volume of 15 μL. PCR reactions were set up
using a QIAgility liquid handling robot and were performed on a Rotor-
Gene Q cycler (Qiagen). The cycling parameters were: 94 °C for 3min
initial denaturation followed by 40 cycles of 95 °C for 5 s, 60 °C for 15 s
and 72 °C for 30 s. Melting curve analysis and agarose gel electro-
phoresis confirmed the specificity of the primers and the absence of
gDNA contamination. Data of three replicates were analysed for each
gene, using the Relative Expression Software Tool 2008 V2.0.7 [37].
2.15. XBP1-assay of endoplasmic reticulum stress
Upon accumulation of unfolded proteins in the endoplasmic re-
ticulum (ER), a 26-nucleotide fragment from the X-box binding protein
1 mRNA (XBP1(U)) is removed with a special splicing mechanism [38].
This shorter mRNA (XBP1(S)) is a frequently used marker of ER-stress.
To study the expression of XBP1(S), previously described primers [39]
were used. As positive control, Ctrl iPSC was treated with 1 μM Tuni-
camycin to induce ER-stress. New RT-PCR primers were also designed
to amplify both the un-spliced and the spliced variants of the XBP1
(Table S6). PCR reactions were performed using Phusion Hot Start II
High-Fidelity DNA Polymerase and 20 ng of the cDNA samples. The
PCR products were visualized on 2% agarose gels.
2.16. Statistical analysis
All results were analysed using Prism 5 (GraphPad Software, La Jolla,
CA, USA) and Microsoft Office 2010 (Microsoft, Redmond, WA, USA)
software. All data on the graphs represent the average of the triplicate
measurements (n=3). The “n” value corresponds to the number of re-
plicates for each cell line. Analysis of data is presented as the mean ± SEM.
Dunnett's method was used to compare the individual groups with control
subjects. In all cases, significance was noted at p < 0.05.
3. Results
3.1. Patient iPSC lines
In this study two families were sampled where infants were diag-
nosed with MPS II disorder. One family with two male infants (MPSII-
1.3 and MPSII-2.5) and their asymptomatic mother (Ctrl-M.1) were
involved, all carrying a pathogenic mutation of the iduronate 2-sulfa-
tase gene (NM_000202.7(IDS):c.85C > T). This single nucleotide var-
iation (SNV) results in a premature termination codon in the iduronate
2-sulfatase gene. From another family one male infant (MPSII-4.1) with
a missense mutation (NM_000202.7(IDS):c.182C > T) causing MPS II
symptoms was involved. The sampling, genetic reprogramming and
characterisation of the iPSC lines were detailed and published else-
where [23–26]. In addition, a sample of a healthy female was used as
non-linked control (Ctrl; Fig. S1). At the time of the sampling, the
MPSII-2.5 and MPSII-4.1 patients were receiving ERT on a regular basis,
with the last ERT performed one week before blood sampling.
3.2. Neuronal differentiation ability of iPSCs revealed an in vitro cellular
disease model
Our aim was to investigate the neuronal phenotype and patho-
mechanism of the MPS II disease in vitro in a cell-based model. PBMCs
were reprogrammed into iPSC lines and their pluripotency was verified as
previously published [23–26]. Hence, all iPSC lines were differentiated
into the neuronal lineage and NPC and TD stages were evaluated. First,
NPC stage was analysed based on the expression of major NPC markers
(NESTIN, SOX1 (SRY- Box 1) and PAX6 (Paired Box 6) using ICC staining,
which did not reveal a marked difference between the healthy and dis-
eased cell lines in early passages (up to passage 7–8) (Fig. 1a). In parallel,
RT-qPCR experiments were performed on early passage NPCs that showed
similar expression levels of PAX6 and NESTIN (Fig. 1b).
Next, the NPCs were terminally differentiated into mature neurons
and their characteristics were analysed after 5 weeks of culture (TD35).
Terminal differentiation resulted in the formation of neuronal net-
works, where both healthy and diseased cells were positive for Tubulin
Beta 3 Class III (TUBB3), the dendritic marker Microtubule-associated
protein 2 (MAP2), and Neurofilament 200 kDa (NF200). Neurons ex-
pressed postsynaptic density protein 95 (PSD95) which indicated the
formation of synapses (Fig. 1c) in all cell lines. This was confirmed by
electron microscopy, where active synapses were identified (Fig. 1d).
During neuronal differentiation, astrocytes also appeared showing Glial
fibrillary acidic protein (GFAP) and Aquaporin-4 (AQP4) expression
(Fig. 1c) regardless of cell line.
Transcriptomic analysis showed that neuronal marker genes TUBB3 and
MAP2 were highly expressed in all TD35 neuronal cultures. The terminal
marker RNA Binding Fox-1 Homolog 3 (RBFOX3, known as NEUN), the
astrocyte-related AQP4, S100 calcium-binding protein β (S100β) and GFAP
were robustly expressed in TD35, highlighting the presence of a glial lineage
in all neuronal cultures (Fig. 1e). The highest GFAP expression was ob-
served in MPSII-4.1 neuronal cultures which was correlated with the
number of GFAP + astrocytes detected in the ICC experiments.
In summary, dual SMAD inhibition-driven neuronal induction resulted
in the formation of MPS II NPC populations with normal proliferative
capacity in early passages and supported their neuronal and astrocyte
differentiation with a transcript- and protein expression pattern similar to
the control line. Until TD35 stage, a mature, synaptically active neuronal
population was successfully differentiated from all genotypes.
3.3. Decreased proliferation capacity of MPS II NPC cultures
When NPC populations were maintained over 8 passages, the pro-
liferation of MPS II NPC cultures slowed or even stopped and 15–30% of
the cells significantly (p < 0.05) decreased their PAX6 and SOX1 protein
expression in the presence of bFGF and EGF. In contrast, control NPCs
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proliferated for up to 12 passages with less reduction in their competence.
This observation was confirmed by FACS analysis, using cell proliferation
marker Ki-67 (MKI67), and early NPC markers PAX6 and SOX1 (Fig. 2a).
Moreover, morphological alterations were also observed in these cultures:
MPS II NPCs started to grow neurites and differentiate into neurons despite
the presence of the mitogens (Fig. 2b).
The capacity for self-renewal/proliferation associated with the
multipotent progenitor state was limited in the MPS II NPC cultures,
and might be related to the disease pathology.
3.4. Patient derived neuronal cells showed increased apoptosis
When MAP2 and TUBB3 ICC staining were compared more thoroughly
in TD35 samples, a stippled staining pattern was identified in some of the
Fig. 2. Characterisation of neuronal precursor cells. a) Early (p5) and late (p9) NPC populations were stained and compared by flow cytometry for neuronal stem
cell (PAX6, SOX1, NESTIN) and cell division (Ki67) markers. With increasing passage number, the proportions of PAX6 and SOX1 positive cells were significantly
decreased in MPSII patient derived cells. This was in accordance with the decreasing number of dividing cells, labelled with Ki67. Data are presented as percentage of
positive cells± SEM (n = 3). *p < 0.05; b) Late passage (p9) NPCs were immunostained against PAX6 (green), NESTIN (red) and SOX1 (magenta), showing a
decreased neuronal stem cell marker expression. Nuclei were counterstained with DAPI (in blue). Scale bar: 20 μm. c) MAP2 and TUBB3 immunostaining showed a
stippled staining pattern in the neurites of MPS II patient-derived TD35 neuronal cultures. d) Fluorescent Caspase 3/7 assay revealed increased Caspase 3/7
activation in MPS II TD35 neuronal cells, but not in the NPCs. Average activity data (n = 3;± SEM) is presented relative to Ctrl samples which was considered as 1.
*p < 0.05.
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dendrites in the patients' samples, suggesting that cell death had occurred
(Fig. 2c). Therefore, a Caspase 3/7 activity assay was performed to study if
the disturbed expression of MAP2 and TUBB3 was linked to apoptotic
events in the diseased neurons. Patients’ TD35 samples showed sig-
nificantly increased expression levels of Caspase3/7 (p < 0.05) compared
to the Ctrl (considered as 1), while the carrier cell line Ctrl-M.1 did not
differ significantly from the Ctrl (p > 0.05; Fig. 2d). We also investigated
the Caspase 3/7 activity in NPC stage cells but did not detect any sig-
nificant difference between healthy and diseased samples (Fig. 2d). Our
results thus demonstrated a significantly increased apoptotic activity in all
three patient-derived TD35 neuronal cultures compared to the Ctrl and the
carrier Ctrl-M.1 cell cultures, suggesting a disease-related phenotype in the
mature neurons.
Next, the expression of Caspase-9 (CASP9), both the pro-caspase
(47 kDa) and cleaved forms (37 kDa and 35 kDa) were detected in the
TD35 cell cultures using Wester-blot. Results showed non-significant
difference in the ratio of cleaved CASP9 compared to the controls (Ctrl
and Ctrl-M.1) (Fig. S2).
3.5. IDS enzyme activity is significantly decreased in MPS II patients’ cells
The presence of the pathogenic IDS mutations in the iPSC lines was
previously validated by Sanger sequencing [23,26]. When the IDS activity
was measured by 4-methylumbelliferyl-α-L-iduronate-2-sulphate fluor-
escent assay [40] in cell lysates of the control, carrier and patient iPSC
lines, no IDS enzyme activity could be detected in the PBMC, iPSC or NPC
stage of MPS II samples, whilst Ctrl and Ctrl-M.1 carrier cells showed
normal IDS activity in all cell types (Fig. 3a). Different IDS enzyme activity
was measured among the different cell types as expected. The assay
confirmed that the studied mutations of the three patients resulted in the
overall loss of the IDS enzyme activity in the primary cells, the PBMCs,
while in vitro cultivation, genetic reprogramming or neuronal differentia-
tion did not restore the enzyme activity.
3.6. GAG accumulation showed correlation with LAMP2 expression in
patient-derived neuronal cells
The IDS enzyme deficiency causes a progressive accumulation of
GAG in the cells of MPS II patients [41]. Therefore, we investigated
whether this phenotype could also be observed in our in vitro cellular
model. The total GAG levels of both the NPCs and the terminally dif-
ferentiated neurons were measured, and all three MPS II NPC cultures
showed lower total GAG levels (p < 0.05) compared to the control and
carrier (Ctrl-M.1) cell lines (Fig. 3b). Marked GAG accumulation was
detected in the neurons of MPSII-1.3 and MPSII-2.5 patients
(p < 0.05), while MPSII-4.1 and Ctrl-M.1 neurons did not differ sig-
nificantly from the Ctrl cell line (p < 0.05; Fig. 3b).
Accumulation of lysosomes was detectable when lysosome-asso-
ciated membrane glycoprotein 2 (LAMP2) ICC staining was performed
on the neuronal cultures (Fig. 3c). We detected a cell type specific
difference in the TD35 patient's samples, with many more LAMP2+
vacuoles in GFAP + astrocytes than in MAP2+ neurons (Fig. 3c).
Western-blot analysis to quantify the amount of LAMP2 revealed in-
creased LAMP2 expression in MPS II NPCs (Fig. 3d). However, in the
TD35 neuronal cultures, significant differences (p < 0.05) were de-
tected only in MPSII-4.1 cell line, where the GFAP expression was found
to be the most robust by RT-qPCR and ICC (Fig. 1c and d).
Next, we investigated if transcription factor EB (TFEB) expression
and subcellular localisation is changed in the affected cells. When TFEB
ICC was performed on NPCs, patient derived NPCs showed increased
TFEB signal in their nuclei more often than the controls (Ctrl, Ctrl-M.1),
which is a sign of the nuclear transport of the protein (Fig. 3e). Western-
blot experiments did not reveal significant difference in the overall
amount of the TFEB protein in the NPC samples (data not shown). The
TD35 neuronal cultures gave similar results to the NPC cultures, when
TFEB localisation was investigated (Fig. 3e).
Together these data suggest the accumulation of both GAGs and
LAMP2+ vacuoles in MPS II iPSC derived neuronal cells, with differences
in abundance between dividing NPCs and terminally differentiated, post-
mitotic neuronal cultures, particularly GFAP + astrocytes.
3.7. Storage vacuole accumulation was prominent in patients’ cells
Next, we questioned whether the cytopathological hallmark of MPS
II affected cells, the accumulation of storage vacuoles, could be de-
tected at the ultrastructural level in the MPS II iPSC derived neuronal
cells. Electron microscopy techniques revealed massive storage vesicle
accumulation in all MPS II NPC cultures (Fig. 4a–e). Vacuoles with
characteristic morphology were classified into four groups (primary
(Pr), globular (Glo), multilamellar (ML) and sequestered (Sq) type) on
the basis of previous studies [42,43] as presented in Fig. S3. The fre-
quency of different vacuole types was determined by semiquantitative
scoring (Table S1).
Unexpectedly, storage vacuoles were also detectable in the healthy
carrier Ctrl-M.1 sample (Fig. 4b and c), although the number of affected
cells was much lower in this culture than in patients' samples. The Pr
vacuole was the most abundant type in all patients’ NPCs, with the
other three types (Glo, ML and Sq vacuoles) also well represented
(Fig. 4d and e; Fig. S3; Table S1).
All types of storage vacuoles were also detectable in the carrier Ctrl-
M.1 and MPS II patients’ TD35 neuronal cultures. Again, the Pr vacuole
was the most frequent type in all MPS II TD35 samples (Fig. 4g–i) while
the Sq type (Fig. S4) was rarer in the MPSII-2.5 and the MPSII-4.1 than
in the MPSII-1.3 TD35 cultures (Table S1). It should be noted that au-
tophagosomes were found rarely in all MPS II cultures.
Storage vacuoles were also detected in the PBMCs of the MPS II pa-
tients (Fig. S5) proving their original existence in the diseased individuals
[44,45] and their independence from the genetic reprogramming and/or
in vitro cultivation. In conclusion, the Pr storage vacuoles were most en-
riched in the MPS II and carrier Ctrl-M.1 NPCs and TD35 cultures, while
other vacuole types accumulated with varying incidence.
3.8. The involvement of late endosomal-lysosomal system in the neuronal
pathomechanism of MPS II
We performed immunogold labelling on NPCs to evaluate the in-
volvement of storage vacuoles in the endosomal-lysosomal system
(ELS), studying RAB5 as an early endosomal marker, RAB7 as a late
endosomal marker, Cathepsin D (CATD) and LAMP2 as lysosomal
markers and RAB2 as a Golgi-derived membrane marker. RAB5 im-
munopositivity was observed on plasma membrane, small membrane
pits, early endosomal elements, internal vesicles and multilamellar
figures of MPS II NPCs (Fig. 5a–c). RAB7 and CATD antisera gave no
reaction on Pr vacuoles (Fig. 5e, i-j), although they labelled ML, larger
multivesicular and Sq types of vacuoles (Fig. 5f, i-j). Analysis of RAB2
labelling revealed positive cisterns and small cytoplasmic vesicles in the
Golgi area, on limiting and inner membranes of storage vesicles (Fig.
S5). These observations raise the possibility of a functional connection
between storage vacuoles and the Golgi complex. LAMP2 was detected
on Pr (Fig. 5h), Glo, ML and Sq type vacuoles as well (Figs. S6a–b). In
addition, we found gold particles on several small cytoplasmic vesicles,
some of which seemed to fuse with other vesicles, for example with
storage vacuoles (Fig. 5g and h).
During the evaluation of ultrathin sections, we noticed the clearance
of undigested material by exocytosis in both NPC and TD cultures. We
found that all types of storage vacuoles were able to fuse with plasma
membrane independent of their content. Exocytosed vesicles detected
by immunocytochemical experiments were positive for RAB7, CATD,
LAMP2 but not RAB5 (Fig. S7). The results of immunogold labelling are
summarized in Table S2.
Next, we performed immunoblot experiments to compare protein
levels in NPCs and TD35 cultures. Western blot experiments for RAB5
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Fig. 3. IDS enzyme activity, total GAGs levels and LAMP2 expression of MPS II neuronal cells. a) IDS enzyme activity measured in the lysate of patients'
mononuclear blood cells (PBMCs), genetically reprogrammed hiPSCs and in their derived NPCs, by 4MU fluorescent assay. Enzyme activity significantly decreased or
dropped to zero in patient samples, in all cell types (MPSII-1.3; MPSII-2.5 and MPSII-4.1), while the enzyme activity was in the normal range in the control and
decreased in the carrier mother (Ctrl-M.1) cells. Data are presented as mean ± SEM (n = 3). *p < 0.05; b) Total GAGs were determined in NPC and neuronal
cultures. Diagrams shows the total GAG levels in μg normalized to 1× 106 cells. Data are presented as mean ± SEM (n = 4). *p < 0.05; c) Representative LAMP2
immunostaining of NPCs and TD35 neuronal cultures combined with NESTIN or MAP2 and GFAP respectively, which showed increased LAMP2 positive vacuole
accumulation in MPS II patient's (MPSII-1.3) neuronal cells, with more prominent accumulation in GFAP positive astrocytes. Scale bar: 10 μm; d) Western blot
analysis confirmed the protein expression of LAMP2 in NPC and TD35 cell lysates. Signals were normalized to GAPDH, data are presented as mean ± SEM (n = 3).
Dunnett's test was performed to evaluate the significance of groups compared with the control (Ctrl). *p < 0.05). e) Representative TFEB immunostaining of NPCs
co-labelled with NESTIN, and TD35 neuronal cultures co-labelled with TUBB3, showing the dominant nuclear localisation of TFEB in MPS II cells. Scale bar: 20 μm.
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showed a significant decrease in MPS II NPCs (p < 0.05), and a ten-
dency to increased expression in all MPS II affected TD35 samples
compared to the Ctrl (Fig. 5; Fig. S6). However, RAB7 (Fig. 5l) and
RAB2 (Fig. S6) were not significantly different in any cultures. All these
data, together with the previously described LAMP2 expression (Fig. 3),
collectively indicate the involvement of the late endosomal-lysosomal
(RAB7, LAMP2 and CATD positive) compartment in storage and
clearance of accumulated material in MPS II.
3.9. Primary storage vesicles are not a part of the endosomal compartment
Extracellular materials destined for degradation, including GAGs,
enter the ELS. To trace this pathway, we treated cells with nanogold
particles to identify endosomal-lysosomal elements and to evaluate
whether there was a connection with Pr storage vesicles. Ctrl and
MPSII-2.5 NPCs were incubated with 5 nm TMA-coated gold nano-
particles [33] at different concentrations (0.5 μM and 1 μM) and treat-
ment times (12 and 24 h). Using electron microscopy, we detected na-
nogold particles on the plasma membrane, and in Glo and Sq type
storage vacuoles, but never in Pr vesicles (Fig. S8). These observations
support the hypothesis that the content of Pr vesicles does not originate
from the ECM.
3.10. Rough endoplasmic reticulum (RER) and Golgi deformations are
characteristic of MPS II affected iPSC derived neuronal cells
Alteration of RER morphology was observed in all MPS II affected
NPC and TD35 cultures. Dilated cisterns were frequently documented in
Fig. 4. Ultrastructure of NPC and TD35 neuronal cultures in MPS II disease. a) Ultrastructure of Ctrl NPCs by EM. Overview of the culture with intact cells
attaching to each other. Insets of panel a: autolysosome (AL), multivesicular body (MVB) and two types of multilamellar bodies (MLB1, MLB2) are visible in cells. b-e)
Storage vacuoles in Ctrl-M.1 and MPSII-1.3 NPCs: primary (Pr, panel b, d, e), globular (Glo, panel b, d, e), multilamellar (ML, panel d) and sequestered (Sq, panel c)
types. Golgi stacks with short cisterns (G) and skein-like deformation (Gs) are shown in panel e. Primary vacuole seems to be in connection with cistern-like element
in panel e (white arrowheads). f) Astrocytes in healthy Ctrl TD35 culture show glycogen granules (Gl), Golgi area with Golgi ribbon formed by three Golgi stacks (G)
and endosomal elements enclosing internal vesicles (ILV) can be seen. Inset demonstrates a multivesicular body filled with dense intraluminal vesicles (ILV). g)
Neuron of Ctrl-M.1 TD35 culture contains primary vesicles (Pr) at well-developed Golgi ribbon (G). Right Golgi stack shows skein-like deformation (Gs). White
arrowhead indicates a phagosome. h-i) Storage vacuoles in MPSII-1.3 TD35 culture. Primary (Pr, panel h, i), globular (Glo, panel h) and sequestered (Sq, panel i)
storage vacuoles can be detected in astrocytes (panel h) and a neuron (panel i). Swollen RER cisterns (black asterisk in panel b, c, d, e, i) are often visible in affected
NPC and TD cells (scale bars: a: 10 μm, f: 2 μm, h, i: 1 μm, b, c, d, e, g, insets on panel a: 500 nm, inset on panel f: 200 nm).
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Fig. 5. RAB5, RAB7, Cathepsin D and LAMP2 expression in MPS II disease neuronal cells. a-j) immunogold labelling in NPC cultures. a-c) RAB5 immunopositivity can
be detected on cell surface (black arrowheads in panel b, c and inset in panel c), in internalizing pits (a) and in early endosomal elements near to the plasma membrane (b).
A sequestered (Sq) storage vacuole contains multilamellar membrane structure (ML) in panel c. RAB5 specific gold particles can only be detected on internalized membrane
whirl (white arrowheads). Inset demonstrates an immuno-negative primary storage vesicle. d-f) Immunogold particles decorate some globular type storage vacuoles (d) and
multilamellar figure (MLF in panel f) after RAB7 immunolabelling. Immuno-negative primary (Pr, panel e) and globular (Glo, panel f) vesicles can be seen as well. Black
arrowheads on panel e indicate small RAB7 positive cytoplasmic vesicles. g-h) LAMP2 immunopositive vesicles in the cytoplasm. g) Arrangement of gold particles on
smaller (black arrowheads) and larger vesicles (white arrowheads). h) Primary storage vesicle with LAMP2 immunopositive limiting membrane (white arrowheads). Small
cytoplasmic vesicles (black arrowheads) seem to be fused with the limiting membrane (black arrow; scale bars: 200 nm). i-j) Cathepsin D (CATD) immunopositivity is
observable at the limiting membrane (black arrowheads on panel i) and at the inner content (white arrowheads on panel j) of storage vacuoles (MLF – myelin figure, Sq –
sequestered type vacuole). Primary vesicles (Pr) are immuno-negative and able to fuse with immunopositive small vesicles (black arrows on panel j). k-l) Western blot
analysis confirmed the protein expression of RAB5 (k), RAB7 (l) in NPC and TD35 cell lysates. Signals were normalized to GAPDH, data are presented as mean ± SEM
(n = 3). Dunnett's test was performed to evaluate the significance of groups compared with the control (Ctrl). *p < 0.05).
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NPCs, even in the carrier Ctrl-M.1 cells (Fig. 4b and c). Wide ribosome
decorated cisterns (Fig. 4d and e) were the most striking in the MPSII-
1.3 cells, whereas ribosome-free swollen cisterns with globular endings
were found in MPSII-4.1 NPCs (Fig. S4c). There were fewer dilated RER
cisterns in MPS II TD35 neuronal cells than in NPCs, although swollen
morphology was detected in astrocytes (Fig. S4) and neurons (Fig. S4)
as well in all MPS II TD35 cultures.
Storage vesicles often clustered in Golgi areas in both MPS II NPC
(Fig. 4e; Figs. S4b–c) and TD35 (Fig. 4g; Fig. S4g) cells. Golgi complexes
showed characteristic deformations in all the disease affected cell lines:
Fig. 6. Endoplasmic reticulum stress and autophagy in MPS II neuronal cultures. a) RT-qPCR assay of XBP1(S) of iPSC derived NPCs and TD35 samples. Values
are expressed as relative expression normalized to the NPC control; b) Representative RER cisterns after localisation of ER chaperones in MPSII-1.3 NPCs. Although
some gold particles associate to ER membrane (black arrowheads), the larger amount of GRP78/BIP and Calreticulin proteins can be visualized in the lumen of
dilated RER cisterns (white arrowheads) (StV – globular storage vacuole; scale bars: 100 nm); c) Expression of CALR gene in patients' and control NPC and TD35
cultures evaluated by RT-qPCR. Values are expressed as relative expression normalized to the Ctrl, set as 1. Data are presented as mean ± SEM (n = 3). *p < 0.05;
d) Western-blot analysis of GRP78, Calreticulin, e) LC3-I and LC3-II proteins in NPC and TD35 samples. LC3-II/LC3-I ratio was determined and presented. Signals
were normalized to GAPDH, Ctrl was set as 1, data are presented as mean ± SEM (n = 3). Dunnett's test was performed to evaluate the significance of groups
compared with control (*p < 0.05).
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fragmented cisterns, skein-like motifs, onion-like stacks, vacuolation
and individual Golgi stacks were frequently documented (Figs. S9b–d).
Ribbon and cistern fragmentation were atypical and vacuolation was
not observed in healthy Ctrl samples (Fig. S9a).
In summary, ultrastructural examination revealed RER and Golgi
deformations in all iPSC derived MPS II and carrier Ctrl-M.1 NPCs and
TD35 cells. Based on these observations we can assume the existence of
ER and Golgi stress in both NPCs and TD35 neuronal cells. According to
our knowledge our study is the first one that documents morphological
characteristics of both ER and Golgi stresses in human neuronal cells
derived from MPS II patients.
3.11. ER-stress is involved in MPS II associated neurodegeneration
Next, we investigated whether the directed neural differentiation
toward NPCs is concomitant with endoplasmic reticulum (ER) stress in
patient and control cell lines using the XBP1-assay. This assay relies on
the observation that upon accumulation of unfolded proteins in the ER,
a 26-nucleotide fragment from the X-box binding protein 1 mRNA
((XBP1(U)) is removed by a special splicing mechanism [38]. This
shorter mRNA ((XBP1(S)) is a frequently used marker of ER-stress. First,
RT-qPCR assay of the XBP1(S) was performed following the previously
described procedure [39]. Interestingly, all MPS II and the carrier NPCs
showed upregulation of XBP1(S) compared to the control (p < 0.05),
whilst TD35 neurons had a different expression pattern (Fig. 6a).
The possibility of stimulated ER stress signalling pathways was
studied by immunolabelling ER chaperones on ultrathin sections.
Intense accumulation of GRP78/BIP and Ca2+ binding ER chaperone
calreticulin (CALR) was detected in extremely dilated RER cisterns of
each MPS II culture (Fig. 6b), but in relatively few cells. The studied ER
chaperones were not detectable in Pr storage vacuoles. There was de-
creased gene expression of CALR in all MPS II NPCs (p < 0.05), with
significantly increased expression observed only in MPSII-4.1 TD35
samples (p < 0.05; Fig. 6c). Moreover, when cell lysates were in-
vestigated with Western-blot CALR expression level was significantly
lower (p < 0.05) in all MPS II affected NPCs compared to the control.
In contrast, the expression of CALR was significantly increased in two of
the MPS II TD35 neuronal cultures (Fig. 6d). There were no significant
differences in the GRP78/BIP protein expression pattern in all NPC
samples (Fig. 6d). In conclusion, the observed disease-specific splicing
pattern of XBP1 in NPC stage and elevated calreticulin expression level
in two of the TD samples, indicating the involvement of ER-stress in the
MPS II cytopathology.
3.12. Autophagy activation
The activation of autophagosome markers was then investigated, to
test whether accumulated storage vacuoles and deformed Golgi stacks
could induce autophagy as an effective clearance mechanism to elim-
inate unwanted and damaged cell organelles. Western-blot revealed
constant, low levels of both LC3-I and LC3-II in NPCs, with no sig-
nificant differences between the cell lines (p > 0.05) (Fig. 6e). In
contrast, in TD35 neuronal cultures Ctrl-M.1 and MPS II patient samples
showed significantly higher LC3-I expression than the Ctrl. However,
LC3-II form level was significantly higher in the carrier cell line and the
MPSII-1.3 patient's sample, while it was the same as of the Ctrl in the
MPSII-2.5 and the MPSII-4.1 TD35 cultures (Fig. 6e). We found that
LC3-I/LC3-II ratio was significantly lower in MPS II affected TD35 cell
cultures than in Ctrl (Fig. 6e). Taken together, these data indicate that
the autophagy was affected by the examined IDS mutations of MPS II
disease.
4. Discussion
By definition, individual rare diseases affect only a minority of the
population but taken together they have a prevalence of> 6% of the
world population. Due to the small number of specific patients and their
wide phenotypic heterogeneity, very few studies have elucidated the
pathophysiological mechanisms of individual rare diseases, so there is
still a lack of available treatment for> 60% of them. The group of ly-
sosomal storage disorders (LSDs) is one set of rare diseases where the
intensification of pathophysiological studies would be important.
Pluripotent stem cell-based research such as disease modelling, drug
screening, and possible clinical translation involving gene therapy are
potential applications in the LSD disease family.
Currently 11 LSDs have been modelled by human iPSCs, high-
lighting the importance of the field and the potential of the technology
(reviewed in Ref. [46]). To explore novel therapeutic pathways and to
address an unmet medical need, we established and described a novel
iPSC-based cellular model which recapitulates the MPS II phenotype in
vitro while identifying an unknown neurological pathomechanism. The
disease-specific iPSC lines were capable of NPC production following
directed differentiation toward the neural lineage, but their remarkably
impaired self-renewal/proliferation capacity revealed the MPS II phe-
notype at the early progenitor stage. However, terminal differentiation
of the NPC cultures revealed mature neuronal cultures, which were
demonstrated on protein expression level and detecting synaptic con-
nections with electron microscopy as well. Detailed ultrastructural
analysis in concert with transcriptomic and proteomic investigations of
the NPC and terminally differentiated stages have led us to the fol-
lowing findings: i) the disease specific storage vacuoles accumulate in
patient-derived NPCs and terminally differentiated neuronal cultures
and are already present in primary PBMCs; ii) primary storage vesicles
seem to be the most prevalent in the disease, although other vacuoles
can be clearly identified in the diseased neuronal cell types; iii) the
degradation of accumulating material is noticeably impaired; iv) cal-
reticulin upregulation, dilated ER cisterns and Golgi malformations are
part of a cytopathology in the TD state; and finally v) in addition to
NPCs, both astrocytes and neurons are affected.
4.1. iPSC based MPS II disease model recapitulate IDS deficiency, GAG and
storage vacuole accumulation
The discovery of human iPSCs [47,48] opened opportunities to
study disease progression during development and to investigate the
disease affected cell types in humans via disease specific iPSC differ-
entiation. Tolar et al. generated Hurler syndrome (MPS IH) specific-
hiPSCs and demonstrated the potential of gene corrected autologous
hematopoietic stem cell production [49]. In MPS II there is only one
report on hiPSC generation, where the cells were derived from a
symptomatic MPS II female patient where skewed X-chromosome in-
activation caused the expression of the mutant IDS allele [50]. Al-
though the results are important regarding the diversity of the disease,
neither the cytopathology nor the mechanism of neurodegeneration
was investigated. We generated MPS II carrier and diseased human iPSC
lines [23,25,26], along with a healthy control, and used these lines as a
model system in this study to investigate MPS II cytopathology, fo-
cusing on the as yet poorly understood neurodegenerative involvement.
Intracellular accumulation of lysosomal storage vacuoles is a cyto-
pathologic hallmark of most LSDs. The ultrastructural morphology of
vacuoles is revealed in some LSDs and some cell types, and the corre-
lation between GAG accumulation and presence of storage vesicles in
MPSs is long-established [41]. Although the cytopathology of neuro-
degeneration in MPS II disease is unknown and details are still not
clear, the connection between perturbed IDS enzyme activity and GAG
turnover and dysfunction of the ELS, ER, Golgi and mitochondria has
been documented in various LSDs [41]. When we studied IDS enzyme
activity and GAG accumulation, we found decreased IDS enzyme ac-
tivity and increased GAG accumulation in patient iPSCs and their
neuronal derivatives. Moreover, increased storage vacuole accumula-
tion was detected in the diseased cells, similar to that in the patients’
original PBMCs. Together these data demonstrated that our iPSC based
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in vitro cellular system could adequately model MPS II cytopathology
and so could be used for the further study of MPS II.
4.2. Disease phenotype is already apparent in the NPC stage
Our results showed that the NPC stage neuronal differentiation ca-
pacity is seriously affected in MPS II disease. NPCs are dividing pre-
cursor cells with an active metabolism that is required to form highly
complex neural structures. ECM is important for proper cell growth,
thus disturbance in GAG metabolism can interrupt proliferation and
could influence differentiation [51]. This was clearly demonstrated by
the decreased proliferative capacity of late passage MPS II NPCs and by
the loss of PAX6 expression. This was in line with morphological
changes, such as when the non-dividing cells became post-mitotic and
started to grow neurites. As ECM components, heparan sulphate pro-
teoglycans (HSPG) bind numerous ligands such as fibroblast growth
factors (FGFs) which are essential for NPC proliferation and regenera-
tion both in vivo and in vitro [21,52,53]. Upon IDS enzyme dysfunction
HSPG metabolism is disturbed, possibly impairing the binding of bFGFs
and affecting the self-renewal/proliferative capacity which leads to
differentiation.
Additional pathological hallmarks of MPS II observed in NPC cul-
tures were elevated levels of primary storage vesicles in those of MPS II
patients, as detected by electron microscopy and by protein expression
of lysosome-associated membrane glycoprotein 2 (LAMP2). However,
we did not detect GAG accumulation at the NPC stage, finding de-
creased intracellular GAG levels compared to the controls. In parallel,
we also documented a significantly lower level of RAB5, and the same
level of RAB7, as in healthy or carrier control NPCs. RAB5 has a central
role in clathrin-mediated endocytosis, early endosome formation and
maturation [54]. While RAB5 is associated with the pathway that
performs uptake of membrane surface receptors and extracellular ma-
terial, RAB7 manages both the endosomal and autophagosomal
pathways, thus the size of the RAB7+ compartment is also related to
the level of macroautophagy (MA) [55]. The RAB7+ vesicles transport
their material to the RAB7 and LAMP2 double positive lysosomal
compartment in healthy cells (Fig. 7a).
A lower rate of endocytosis has been documented in fibroblasts from
patients with several types of LSDs (type A Niemann-Pick, type C
Niemann-Pick, Fabry and Gaucher diseases) [56], MPS II and MPS IV
diseases [57]. These data are consistent with the significantly lower
level of RAB5 detected in iPSC derived MPS II NPC cultures, which
could limit the rate of endocytosis in these cells.
Both endocytic and autophagic pathways deliver materials into the
lysosomal RAB7+ and LAMP2+ compartment (see Fig. 7a). MPS II
NPC cell lines showed no LC3-I upregulation, therefore we can assume
that this pathway does not load this compartment significantly. Pro-
liferation and cell death provide a good possibility to manage accu-
mulation of intracellular GAGs and damaged cell organelles at tissue
level, therefore it may be an adaptive response to LSD, even if it leads to
premature differentiation.
We hypothesize that the intensity of GAG uptake decreases due to a
reduction of accessible RAB5 (RAB5+ membranes were enclosed in
storage vacuoles), and because NPCs are able to exocytose intracellular
GAGs. It is known that both late endosomes (multivesicular bodies) and
lysosomes can fuse with the plasma membrane to release their contents
to the extracellular space (Fig. 7a), even if they stored undigested
material. Although this unconventional mode of secretion is poorly
understood, induction of this pathway via the overexpression of tran-
scription factor EB (TFEB) reduced the storage material load and
LAMP1 compartment in a muscle cell culture system and a mouse
model of Pompe disease [58], in mouse models of MPS IIIA (Sanfilippo
syndrome), and in a multiple sulfatase deficiency (MSD) model [59],
which was in accordance with our TFEB immunolocalization data. In
addition to TFEB, mammalian RAB2 has also been found to promote
late endosomal exocytosis in cancer cells [60]. In accordance with these
Fig. 7. Model of endocytic and autophagic pathways of healthy and MPS II disease astrocytes. a) Pathways and detected vesicles in healthy cells. Gold
nanoparticles (Au NPs) taken up from extracellular matrix (ECM) are transported through the endocytic pathway. Gold particles enter the cell and get into the
RAB5+ early endosome (EE) then reach the RAB7+ late endosomal compartment (LE) due to endosomal maturation. Golgi derived RAB2+ lysosomal membrane
protein carrier (LMPc) vesicle carries LAMP2 and other lysosomal membrane components and forms endolysosome (EL) by fusing with the LE element. A part of the
lysosomal membrane with integrated proteins is able to pinch off from functioning endolysosome for recycling (see grey arrows between LMPc and EL). Undigested
materials like gold particles may leave the cell via lysosomal exocytosis. Autophagosome formed by the contribution of LC3-I conversion to LC3-II changes to RAB7+
autophagic vacuole (AV) by maturation or fuses with late endosomal element to form amphisome (AS). Fusion of autophagic vacuole and LMPc results in a RAB7+/
LAMP2+ autolysosome (AL). Multivesicular bodies (MVB) and multilamellar bodies (MLB) may be a part of both RAB7+ and RAB7+/LAMP2+ compartments and
may contain material of extra- and intracellular origin as well. b) Pathways and vesicles in MPS II disease cell. Note that LMPc vesicles do not fuse with RAB7+ late
endosomal elements (LE) or autophagic vacuoles (AV), but unite to form a primary storage vesicle (Pr). Gold particles label the early (EE) and late (LE, EL) endosomal
elements but do not reach primary vesicles. Primary vesicles are able to fuse with nonfunctional LAMP2+ lysosomes to form globular (Glo), multilamellar (ML) and
sequestered (Sq) type storage vacuoles, which contain gold particles. Undigested material accumulates by shuttling between functional RAB7+/LAMP2+ en-
dolysosome (EL) and nonfunctional LAMP2+ compartment. TFEB promotes RAB2+ LMPc production by Golgi, lysosomal exocytosis and LC3-I transcription as well,
although LC3 maturation is probably inhibited in MPS II disease.
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data, our ultrastructural investigation revealed the presence of RAB7,
CATD and LAMP2 positive storage vacuoles from the very moment of
exocytosis taking place in NPC cultures. This mechanism can explain
how cerebrospinal fluid in the CNS could concentrate GAGs and GAG
fragments. To our knowledge this is the first study which has explored
the developmental aspects of the disease in neuronal tissue.
4.3. Involvement of ELS by impaired GAG degradation in mature neurons
and astrocytes
In contrast to NPCs, mature neurons and astrocytes (TD35) of the
two patient cell lines with PTC showed significantly increased in-
tracellular GAG accumulation, while the RAB5, RAB7, and LAMP2 le-
vels were similar to those in a healthy Ctrl sample. Accordingly, we can
hypothesize that neither the endosomal nor lysosomal compartment
was responsible for GAG accumulation in the siblings’ cell lines.
However, the patient cell line with the missense mutation did not differ
significantly from the control in any of these parameters, consequently
MPSII-4.1 TD35 cells did not accumulate GAGs. These conclusions raise
the possibility of disturbances of the autophagy pathway, and alteration
of neuronal differentiation.
4.4. Autophagosome formation is induced in neuronal cultures of MPS II
cell lines
In our experiments, a significantly increased level of LC3-I was de-
tected in all MPS II affected TD35 cultures, consistent with the thought
that increased basal autophagy is part of the cytopathology of most
LSDs [61]. The role of the mammalian target of rapamycin (mTORC1)
in MA regulation is widely discussed. Impaired lysosomal functions
attenuate mTOR activity, leading to the activation of TFEB signalling
and resulting in the activation of both lysosomal [62,63], and autop-
hagy genes [63]. A predominant nuclear localisation of TFEB has been
detected in cultured cells [64] and in a mouse model [62,65] of MPS II.
In our study, we observed similar localisation of TFEB protein, with
clear dominance in the nuclei of diseased cells of MPS II patients
(Fig. 3e). Documented mitochondrial dysfunction in LSDs [66] ne-
cessarily increases the cytoplasmic AMP/ATP ratio [67], which can also
influence mTOR activity through an AMP-activated protein kinase
(AMPK) pathway [68,69].
Involvement of autophagy in the self-renewal and differentiation of
neural progenitor cells is well known [70]. Based on the increased LC3-I
level, we hypothesize that both AMPK and TFEB pathways might be
activated in MPS II neurons and astrocytes, where autophagosome
formation was induced.
4.5. MPS II impair LC3 processing in TD35 cultures
We detected a significantly lower LC3-II/LC3-I ratio in all MPS II
affected cultures in contrast to the Ctrl sample. Macroautophagy is a
highly organized degradation pathway essential for cellular home-
ostasis, survival and differentiation. Initiation of MA is a multistep
process that involves the formation of an isolating membrane (phago-
phore) that closes to form a double membrane vesicle, an autophago-
some. Association of microtubule-associated protein 1 light chain 3
(LC3) and the isolating membrane is an indispensable step in autop-
hagosome formation. LC3 is synthesized as precursor form (proLC3),
which is cleaved to its soluble form LC3-I. Lipidation of LC3-I results in
the production of the functional, membrane-bound form, LC3-II.
Autophagosomes then undergo maturation into autolysosomes, in
which the inner membrane-bound LC3-II is degraded by lysosomal
hydrolases [71,72].
Based on some fundamental studies in the field of autophagy
[73,74], we hypothesize that there is a low LC3-I→LC3-II transition rate
in all MPS II affected TD35 cell cultures. The possibility of impaired
autophagosome formation is corroborated by our only rare observation
of autophagosomes in MPS II TD35 cells in ultrastructural studies. Be-
cause autophagosome accumulation is thought to be common in many
storage diseases [72], our findings could extend the knowledge on the
cytopathology of LSDs.
4.6. Identity of storage vacuoles
The size of the RAB7 positive compartment was not affected in MPS
II neuronal cells, even though the LAMP2 level was increased in all MPS
II disease cell lines. The LAMP2+ (endo- and autolysosomes) and
RAB7+ (late endosomes, endo- and autolysosomes) compartments are
partly overlapping in healthy cells, except for newly formed lysosomal
membrane carriers generated by the Golgi complex (Fig. 7a). An in-
crease in the LAMP2, but not the RAB7 compartment in MPS II diseased
cells surely then implicates the involvement of the lysosomal system in
the cytopathology of MPS II.
Theoretically, there are two possible explanations for these results.
On the one hand, the increase in the LAMP2 compartment could ori-
ginate from the loss of the RAB7 marker from the LAMP2 and RAB7
double positive compartment, leading to the accumulation of uni-
dentified storage vacuole material in this compartment. According to
the traditional concept, this material would be undigested GAGs that
accumulated due to the IDS deficiency. To our knowledge RAB7 is not
necessary for lysosomal exocytosis [75], and we proved that the LAMP2
positive compartment is able to clear its storage material via exocytosis.
This assumption is compatible with the results of Spampanato et al.
who identified that the exocytosed vesicles were both LAMP1 and LC3
positive in Pompe disease [58].
On the other hand, LAMP2 but not RAB7 positive membranes are
found on the LAMP-containing biosynthetic carriers released from the
Golgi. Lysosomal membrane proteins, like LAMPs, are transported di-
rectly to the late endosomal compartment by non-clathrin coated ve-
sicles called lysosomal membrane protein carriers (LMPc) [60]. Golgi
derived LMPc are RAB7 negative but may carry Golgi markers (Fig. 7a).
In Drosophila garland cells RAB2 has been shown to be indispensable for
lysosomal membrane protein delivery to late endosomes. Lund et al.
reported that LMP carrier vesicles accumulated and seemed to fuse with
each other or with non-degradative storage lysosomes in the absence of
RAB2 [60]. These results are consistent with our observations that
storage vesicles are not necessarily RAB7 or CATD positive but are able
to fuse with each other. In addition, we observed small cytoplasmic
vesicles that were RAB2 and LAMP2 immunopositive and seemed to
fuse with each other.
Since primary storage vesicles are formed by LMP carriers, they are
RAB2 and LAMP2 positive and originally contain no GAGs. Vesicles are
able to fuse with each other and with RAB7 positive endo- and auto-
lysosomes, meaning that undigested GAGs and inner membranes enter
storage vesicles indirectly, via endolysosomes. The resulting Glo, ML
and Sq types of storage vacuoles may recycle into a LAMP2 positive and
RAB7 negative compartment (see Fig. 7a).
Involvement of the Golgi in MPS cytopathology in MPS IIIB
(Sanfilippo syndrome) caused by mutation of N-acetyl-alpha-glucosa-
minidase (NAG) was suggested by Vitry et al. who detected Golgi ma-
trix 130 (GM130, also known as golgin subfamily A member 2,
GOLGA2) and LAMP-1, but not early endosome antigen 1 (EEA1)
marker on storage vacuoles of cortical neurons in a mouse model. In
their comprehensive study they demonstrated that storage vacuoles did
not receive materials from the endocytic pathway [76]. These data are
consistent with our results related to the early endosomal compartment,
i.e. that the limiting membrane of each storage vacuole types was RAB5
negative, and we did not detect functionalized nanoparticles in primary
storage vesicles, although gold particles appeared in Glo, ML and Sq
type vacuoles (Fig. 7b).
However, Vitry et al. found that the autophagic pathway was not
affected in MPS IIIB, as the same LC3 pattern was detected by Western
blot in both diseased and control cortical cultures [76]. While this latter
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observation is the same as ours in iPSC derived NPC cultures, MPS II
TD35 cells showed higher LC3-I level than Ctrl cell lines. Finally, Vitry
et al. observed Golgi deformations including wider cisterns, internal
bulbs and dilated saccules in MPS IIIB cortical neurons and suggested
the impact of Golgi complex disorganisation in the formation of the
cytopathology [76]. We detected very similar deformations in Golgi
structure in the iPSC derived MPS II model. To determine whether Golgi
stress has a role in initiating the formation of storage vacuoles, or it is
an outcome of disturbances in the lysosomal and/or ER compartment
needs detailed examination.
4.7. Role of ER in MPS II cytopathology
Our first observation related to ER stress was the frequent occur-
rence of dilated ER cisterns both in MPS II NPC cells and TD35 cultures.
In response to stress conditions, like accumulation of misfolded proteins
or Ca2+ depletion in ER cisterns, GRP78/BIP dissociates from UPR
(unfolded protein response) sensors and translocates from the ER
membrane to the lumen, ultimately leading to the alternative splicing of
transcription factor XBP1 (X-box binding protein 1) mRNA (XBP1(U)).
The shorter XBP1 mRNA (XBP1(S)) is frequently used as a marker of ER
stress, but while we found a significantly increased level of XBP1(S) in
MPS II NPCs, this seemed to be independent of the levels of two ex-
amined ER chaperones, GRP78/BIP and calreticulin.
Involvement of the UPR in LSDs is controversial. The possibility of
UPR activation in LSD pathogenesis may be influenced by tissue type,
extent and type of the accumulated substance, and the type of the
mutation. Although Villani et al. detected no XBP1(S) in human MPS II
fibroblast cells [77], we have demonstrated significantly elevated level
of the spliced form of the XBP1 in MPS II neuronal progenitor cells.
Accordingly, we can state that ER stress is involved in the cyto-
pathology of MPS II in neuronal cells in NPC stage, and it presumably
activates the IRE1 (inositol-requiring kinase 1) signalling pathway.
Although ER stress is able to induce apoptosis [78], the IRE1 pathway is
thought to be an adaptive, anti-apoptotic branch of UPR [79], which
explains why we did not find elevated caspase 3/7 activity in patient
derived NPCs.
In contrast to the NPC state, the IRE1 branch of UPR was not active
(see the XBP1(S) levels) and GRP78/BIP and calreticulin seemed to be
slightly upregulated in TD35 cultures. Calreticulin is the primary calcium-
buffering chaperone of the RER, implicated in both the storage and release
of Ca2+ from ER cisterns [80,81]. We assume that Ca2+ depletion from
the ER caused the increased cytoplasmic Ca2+ level in MPS II TD35 cells.
The elevation of cytoplasmic Ca2+ is thought to be a significant problem
in LSD affected cells due to the impaired sequestering capacity of damaged
mitochondria [66]. Sustained elevation of cytoplasmic Ca2+ level and
increased ion transfer from ER to mitochondrion are thought to have a
pro-apoptotic effect [81,82]. In the first case activated calpain-9 (CAN9)
cleaves pro-caspase 3/7 [83], in the latter case cytochrome c (CYC) release
from damaged mitochondria results in effector caspase activation through
Caspase 9 (CASP9) [82,83]. Although we detected a similar amount of
pro-Caspase 9 (the uncleaved form) and the cleaved forms in healthy and
MPS II TD cultures, it might not correlate the exact activity of the CASP9.
The precise mechanism of CASP9 activation is uncleared. Several experi-
mental data indicate that uncleaved pro-Caspase 9 may be activated by
dimer formation [84] on a platform provided by cytochrome c binding
apoptosome [84]. Thus, the higher band (47 kDa) detected by Western-
blot might origin from both inactive zymogen and the active, unprocessed
CASP9 forms. Cleaved CASP9 thought to be involved in timing function in
apoptosis induction [85]. Although we measured CASP3/7 activity, we
assume that the significantly high CASP3/7 activity in all disease-affected
TD cultures refers to elevated CASP9 activity. Although the ratio of un-
cleaved and proteolytically cleaved CASP9 is not affected by MPS II dis-
ease, knowing the complex regulation of CASP9 activity [84] we suppose
that this balance is shifted towards the inhibition of cell death in healthy
cells and towards the initiation of apoptosis in MPS II cells.
Taken together, our findings suggest the depletion of luminal Ca2+
storage of ER, elevated ion concentration in cytoplasm and increased
sensitivity to apoptosis in MPS II neuronal and glial cells. We found
significantly higher Caspase3/7 activity in patient derived TD35 cul-
tures compared to the healthy Ctrl and carrier Ctrl-M.1 samples which
might be related to both apoptosis and synaptic pruning in the maturing
neuronal cultures.
4.8. Astrocytes are the primarily affected cells in MPS II neuronal cultures
In one of the LSDs, multiple sulfatase deficiency (MSD), caused by
mutations in the sulfatase modifying factor 1 (SUMF1) gene [86],
massive vacuolisation of GFAP positive astrocytes in the brain of sumf1
mutant mice has been reported. Vacuoles co-localized with ubiquitin
positive aggregates in both neurons and microglial cells corresponding
to the cytoplasmic increase of P62/SQSTM1 [86]. In our study we ob-
served increased LAMP2+ vacuolisation in GFAP positive astrocytes in
the patients’ TD35 samples. Interestingly, this phenotype was observed
in some of the carrier mother (Ctrl-M.1) neuronal samples as well,
suggesting she was affected by the disease at the cellular level. MPS II
neuronal cultures showed massive storage vacuole accumulation with
increased cell death (increased Caspase 3/7 activity and LC3 level),
which was more prevalent in astrocytes. This cell type specific differ-
ence might be in correlation with the role of astrocytes in the CNS, as
they supply energy to neurons, maintain brain homeostasis through
multiple dynamic equilibrium adjustments and recycling, and protect
neurons against oxidative stress [87]. Astrocyte dysfunction is observed
in numerous LSDs and is suggested to impact neurodegeneration [88],
as in several other neurodegenerative disorders [87]. Our results de-
monstrate that when astrocytes are impaired in their ability to support
differentiation and survival of cortical neurons, it may lead to cell death
and neurodegeneration at the tissue level.
4.9. Are carriers asymptomatic on a cellular level?
We have to draw attention to the parameters of the carrier Ctrl-M.1 cell
line. MPS II is an X-linked, recessive disorder: female carriers are healthy
with a mutant and a wild-type allele. We identified storage vacuoles as
cytopathological hallmarks of MPS II in her iPSC derived NPCs and TD
cells, albeit rarely, despite her apparently healthy phenotype.
X chromosome inactivation (XCI) is transcriptional silencing of ma-
ternal or paternal X chromosome in female mammals. XCI patterns vary
from tissue to tissue [89], therefore females are mosaic for the expression
of X-linked genes [90]. Although symptomatic female carriers were
documented in cases of Fabry [91] and Hunter disease [92], the XCI
pattern was not correlated with enzymatic levels of α-Galactosidase A or
IDS enzyme, respectively [91]. We know that XCI is incomplete in hu-
mans, and the identification of the IDS gene as “inactive” and not an
“escape” gene was made in a comprehensive study by Tukiainen et al.
[93]. However, upon genetic reprogramming the epigenetic pattern of
founder cells changes, which could lead to altered expression following
tissue specific differentiation of the reprogrammed cells [94,95].
5. Conclusion
To our knowledge, our study is the first comprehensive character-
isation of MPS II affected neuronal cells in vitro. We documented an
elevated level of lysosomal marker LAMP2 and a decreased level of
intracellular GAG accumulation in our iPSC derived NPC and neuron
cultures and provided two possible explanations for the origin of sto-
rage vacuoles. One of them is based on the traditional concept that
focuses on an endocytic origin of storage vesicles and considers them to
be part of the disturbed lysosomal system. The other hypothesis high-
lights the possible central role of LMP vesicles in the formation of
storage vacuoles, but indicates further questions, regarding UPR in-
duction or the reason behind the impaired fusion between LMP carriers
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and functional lysosomes in MPS II.
We established and defined an iPSC based in vitro cellular model for
the study of MPS II cellular pathology. We concluded that NPC cultures
could provide a good model system for the examination of basic cyto-
pathological events in MPS II, because NPC cultures showed more si-
milarity with disease-associated parameters than TD35 cultures despite
their genetic background. In contrast, TD35 cultures provide an effec-
tive in vitro model for the study of the involvement of different cell
types in the cytopathological features of the disease. Although our
system was used for modelling disease neuropathology, the pluripotent
nature of iPSCs means that it offers a tool for drug testing, gene therapy
studies, and further study to understand the disorder at the cellular
level, in a range of cell types that are seriously affected by this disease,
which currently has no efficient treatment. Our study provides novel
information on the advancement of the disease, which opens the pos-
sibility of finding biomarkers helping to identify the disease as early as
possible.
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